Serum phospholipid fatty acids and prostate cancer risk: Results from the prostate cancer prevention trial

American Journal of Epidemiology

Volumn 173, Issue 12, 2011, Pages 1429-1439

  Brasky, Theodore M ^a,b   Till, Cathee ^a   White, Emily ^a,b   Neuhouser, Marian L ^a   Song, Xiaoling ^a   Goodman, Phyllis ^a   Thompson, Ian M ^c   King, Irena B ^d   Albanes, Demetrius ^e   Kristal, Alan R ^b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c University of Texas Health Science Center   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

fatty acids; histology; inflammation; phospholipids; prostatic neoplasms; serum

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; FINASTERIDE; ICOSAPENTAENOIC ACID; LINOLENIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO;

AGE CLASS; CANCER; CONCENTRATION (COMPOSITION); CONFIDENCE INTERVAL; DISEASE CONTROL; DISEASE PREVALENCE; FATTY ACID; HEALTH RISK; HISTOLOGY; PHOSPHOLIPID; REGRESSION ANALYSIS; RISK FACTOR; SERUM; TEMPORAL ANALYSIS;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER GRADING; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FAMILY HISTORY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROSTATE BIOPSY; PROSTATE CANCER; SMOKING; TREATMENT OUTCOME;

5-ALPHA REDUCTASE INHIBITORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 79958863665     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr027     Document Type: Article

References (36)

1. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4): 256-269. (Pubitemid 46486616)
2. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 2004;171(2 pt 2):S36-S40. (Pubitemid 38090420)
3. Bardia A, Platz EA, Yegnasubramanian S, et al. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol. 2009;9(4): 419-426.
4. Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer. 2010;127(7):1680-1691.
5. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2004;64(9):3334-3343. (Pubitemid 38581441)
6. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000;164(3 pt 1): 820-825. (Pubitemid 30637640)
7. Narayanan BA, Narayanan NK, Pittman B, et al. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res. 2004;10(22): 7727-7737. (Pubitemid 39557538)
8. Chapkin RS, Kim W, Lupton JR, et al. Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids. 2009;81(2-3):187-191.
9. Mozaffarian D. trans-Fatty acids-effects on systemic inflammation and endothelial function. Atheroscler Suppl. 2006;7(2):29-32.
10. Chavarro JE, Stampfer MJ, Campos H, et al. A prospective study of trans-fatty acid levels in blood and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(1): 95-101. (Pubitemid 351196278)
11. Chavarro JE, Stampfer MJ, Li H, et al. A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16(7): 1364-1370. (Pubitemid 47076865)
12. Crowe FL, Allen NE, Appleby PN, et al. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2008;88(5):1353-1363.
13. Gann PH, Hennekens CH, Sacks FM, et al. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst. 1994;86(4):281-286. (Pubitemid 24057406)
14. Harvei S, Bjerve KS, Tretli S, et al. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer. 1997;71(4):545-551. (Pubitemid 27239362)
15. King IB, Kristal AR, Schaffer S, et al. Serum trans-fatty acids are associated with risk of prostate cancer in b-Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev. 2005;14(4):988-992. (Pubitemid 40478568)
16. Laaksonen DE, Laukkanen JA, Niskanen L, et al. Serum linoleic and total polyunsaturated fatty acids in relation to prostate and other cancers: a population-based cohort study. Int J Cancer. 2004;111(3):444-450. (Pubitemid 38998828)
17. Männistö S, Pietinen P, Virtanen MJ, et al. Fatty acids and risk of prostate cancer in a nested case-control study in male smokers. Cancer Epidemiol Biomarkers Prev. 2003;12(12): 1422-1428. (Pubitemid 38031744)
18. Park SY, Wilkens LR, Henning SM, et al. Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort. Cancer Causes Control. 2009; 20(2):211-223.
19. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. (Pubitemid 36859473)
20. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98(16):1128-1133. (Pubitemid 44288787)
21. Gleason DF. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr. 1988;7:15-18.
22. Kristal AR, King IB, Albanes D, et al. Centralized blood processing for the Selenium and Vitamin E Cancer Prevention Trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiol Biomarkers Prev. 2005;14(3):727-730. (Pubitemid 40489223)
23. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497-509.
24. Schlierf G, Wood P. Quantitative determination of plasma free fatty acids and triglycerides by thin-layer chromatography. J Lipid Res. 1965;6:317-319.
25. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res. 1986;27(1):114-120. (Pubitemid 16045295)
26. Breslow NE, Day NE, eds. Statistical methods in cancer research. Vol I. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer; 1980. (IARC scientific publication no. 32).
27. MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA. 2006;295(4):403-415. (Pubitemid 43144977)
28. Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr. 2010;92(5):1223-1233.
29. Brasky TM, Kristal AR, Navarro SL, et al. Specialty supplements and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort. Nutr Cancer. In press.
30. Kim W, McMurray DN, Chapkin RS. Chemotherapeutic properties of n-3 polyunsaturated fatty acids-old concepts and new insights. Immunol Endocr Metab Agents Med Chem. 2009;9(1):38-44.
31. Calder PC, Yaqoob P. Omega-3 polyunsaturated fatty acids and human health outcomes. Biofactors. 2009;35(3):266-272.
32. Kristal AR, Arnold KB, Neuhouser ML, et al. Diet, supplement use, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2010; 172(5):566-577.
33. Remig V, Franklin B, Margolis S, et al. Trans fats in America: a review of their use, consumption, health implications, and regulation. J Am Diet Assoc. 2010;110(4):585-592.
34. Mozaffarian D, Katan MB, Ascherio A, et al. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006;354(15): 1601-1613.
35. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246.
36. Chow CK. Fatty acid composition of plasma phospholipids and risk of prostate cancer. Am J Clin Nutr. 2009;89(6):1946; author reply 1946-1947.